{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:23:06Z","timestamp":1795112586573,"version":"4.10.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) is commonly comorbid with metabolic syndrome; however, MASH can occur in the absence of metabolic syndrome. This retrospective cohort study evaluated the patient characteristics, healthcare utilization, and healthcare costs among patients with MASH with and without metabolic syndrome, obesity, and type 2 diabetes\/elevated fasting glucose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a linked dataset of electronic health records (Veradigm Network EHR) and claims (Komodo Health), we identified adults with a MASH diagnosis code (7\/1\/2018-3\/15\/2023) and \u226512 months of continuous enrollment pre- and post-MASH diagnosis. Patients with other causes of liver disease, gestational or type 1 diabetes, or bariatric surgery were excluded. Six cohorts were identified: 1) MASH with metabolic syndrome, 2) MASH without metabolic syndrome, 3) MASH with body mass index (BMI) &lt;25, 4) MASH with a BMI &lt;25 and metabolic syndrome, 5) MASH with a BMI &lt;25 without metabolic syndrome, and 6) MASH with a BMI &lt;25 without metabolic syndrome or type 2 diabetes\/elevated fasting glucose. We captured demographics, clinical characteristics, all-cause healthcare utilization, and costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 98,199 patients with MASH, of which 34.4% did not have metabolic syndrome, and 3.1% had a BMI &lt;25. Mean (standard deviation) annualized all-cause healthcare costs exceeded $19,000 in all cohorts and ranged from $19,018 ($60,359) among patients with a BMI &lt;25 without metabolic syndrome or type 2 diabetes\/elevated fasting glucose to $32,592 ($337,462) among patients with metabolic syndrome. Median (interquartile range) costs ranged from $5,336 ($2,085-$14,839) to $11,373 ($4,478-$27,243), and mean costs after excluding the top 1% of spenders ranged from $14,355 ($25,868) to $21,878 ($30,755). Trends were consistent when the analysis was expanded to include patients without a documented BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolic syndrome is commonly comorbid with MASH; however, all-cause healthcare costs remain high even among the subpopulation without metabolic syndrome, elevated BMI, or type 2 diabetes\/elevated fasting glucose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04787-5","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:55:39Z","timestamp":1775469339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Burden of metabolic dysfunction-associated steatohepatitis, with and without metabolic syndrome, obesity, or diabetes"],"prefix":"10.1186","volume":"26","author":[{"given":"Elliot B.","family":"Tapper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessamine P.","family":"Winer-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machaon","family":"Bonafede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yestle","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"1","key":"4787_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"12","key":"4787_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175\u201383.","journal-title":"JAMA"},{"issue":"3","key":"4787_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","volume":"13","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, et al. The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States. J Clin Exp Hepatol. 2022;13(3):454.","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"4787_CR4","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","volume":"2","author":"J O\u2019Hara","year":"2020","unstructured":"O\u2019Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep. 2020;2(5):100142.","journal-title":"JHEP Rep"},{"issue":"3","key":"4787_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","volume":"1","author":"MM Balp","year":"2019","unstructured":"Balp MM, Krieger N, Przybysz R, Way N, Cai J, Zappe D, et al. The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. JHEP Rep. 2019;1(3):154\u201361.","journal-title":"JHEP Rep"},{"issue":"1","key":"4787_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-023-02726-2","volume":"23","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Krieger N, Przybysz R, Way N, Cai J, Zappe D, et al. The burden of nonalcoholic steatohepatitis (NASH) in the United States. BMC Gastroenterol. 2023;23(1):109.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"4787_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cld.2023.01.002","volume":"27","author":"F Bril","year":"2023","unstructured":"Bril F, Sanyal A, Cusi K. Metabolic syndrome and its association with nonalcoholic steatohepatitis. Clin Liver Dis. 2023;27(2):187\u2013210.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"4787_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12(1):60.","journal-title":"Diabetol Metab Syndr"},{"issue":"11\u201312","key":"4787_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15015","volume":"48","author":"J Ampuero","year":"2018","unstructured":"Ampuero J, Aller R, Gallego-Dur\u00e1n R, Banales JM, Crespo J, Garc\u00eda-Monz\u00f3n C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11\u201312):1260\u201370.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4787_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.18553\/jmcp.2021.20410","volume":"27","author":"J Cawley","year":"2021","unstructured":"Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenyach T, Smolarz BG, et al. Direct medical costs of obesity in the United States and the most populous states. JMCP. 2021;27(3):354\u201366.","journal-title":"JMCP"},{"issue":"3","key":"4787_CR11","doi-asserted-by":"publisher","first-page":"e0247307","DOI":"10.1371\/journal.pone.0247307","volume":"16","author":"ZJ Ward","year":"2021","unstructured":"Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE. 2021;16(3):e0247307.","journal-title":"PLoS ONE"},{"issue":"1","key":"4787_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","volume":"47","author":"ED Parker","year":"2023","unstructured":"Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023;47(1):26\u201343.","journal-title":"Diabetes Care"},{"issue":"11","key":"4787_CR13","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/03007995.2023.2262926","volume":"39","author":"J Fishman","year":"2023","unstructured":"Fishman J, Tapper EB, Dodge S, Miller K, Lewandowski D, Bogdanov A, et al. The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data. Curr Med Res Opin. 2023;39(11):1425\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"4787_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/dc19-1113","volume":"43","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Tampi RP, Racila A, Qiu Y, Burns L, Younossi I, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. Diabetes Care. 2020;43(2):283\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"4787_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/MCG.0000000000001409","volume":"55","author":"RJ Wong","year":"2021","unstructured":"Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. J Clin Gastroenterol. 2021;55(10):891\u2013902.","journal-title":"J Clin Gastroenterol"},{"key":"4787_CR16","unstructured":"Health Insurance Portability and Accountability Act of. 1996, Pub. L. 104\u2013191 (1996) [Internet]. Pub. L. 104\u2013191 Aug 21, 1996. Available from: https:\/\/www.govinfo.gov\/app\/details\/PLAW-104publ191\/summary"},{"key":"4787_CR17","unstructured":"Standards for Privacy of Individually Identifiable Health Information, 45\u00a0C.F.R. \u00a7 164.514. (2001) [Internet]. Available from: https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-C\/part-164"},{"issue":"10","key":"4787_CR18","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med. 2007;4(10):e296.","journal-title":"PLoS Med"},{"key":"4787_CR19","doi-asserted-by":"crossref","unstructured":"Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640\u20135.","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"issue":"6","key":"4787_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"4787_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.amjcard.2015.11.035","volume":"117","author":"RGW Quek","year":"2016","unstructured":"Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND. A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event. Am J Cardiol. 2016;117(4):495\u2013500.","journal-title":"Am J Cardiol"},{"key":"4787_CR22","doi-asserted-by":"crossref","unstructured":"Tapper EB, Bonafede M, Fishman J, Dodge S, Miller K, Zeng N et al. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis. J Med Econ. 2023;1\u201314.","DOI":"10.1080\/13696998.2023.2184967"},{"issue":"7","key":"4787_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep4.1524","volume":"4","author":"SC Gordon","year":"2020","unstructured":"Gordon SC, Kachru N, Parker E, Korrer S, Ozbay AB, Wong RJ. Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the Fibrosis-4 Score. Hepatol Commun. 2020;4(7):998\u20131011.","journal-title":"Hepatol Commun"},{"issue":"12","key":"4787_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131\u201341.","journal-title":"N Engl J Med"},{"issue":"9","key":"4787_CR25","doi-asserted-by":"publisher","first-page":"e13767","DOI":"10.1111\/obr.13767","volume":"25","author":"JP Bennett","year":"2024","unstructured":"Bennett JP, Prado CM, Heymsfield SB, Shepherd JA. Evaluation of visceral adipose tissue thresholds for elevated metabolic syndrome risk across diverse populations: A systematic review. Obes Rev. 2024;25(9):e13767.","journal-title":"Obes Rev"},{"issue":"12","key":"4787_CR26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2014.07.017","volume":"7","author":"RV Shah","year":"2014","unstructured":"Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. JACC Cardiovasc Imaging. 2014;7(12):1221\u201335.","journal-title":"JACC Cardiovasc Imaging"},{"key":"4787_CR27","doi-asserted-by":"crossref","unstructured":"Pu F, He R, Wei Y, Gong J, Mu D, Shi L et al. The accuracy of visceral adipose tissue for the screening of metabolic syndrome: A systematic review and meta-analysis. Obes Rev. 2025;e70064.","DOI":"10.1111\/obr.70064"},{"issue":"2","key":"4787_CR28","doi-asserted-by":"publisher","first-page":"e0386","DOI":"10.1097\/HC9.0000000000000386","volume":"8","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, Byrne CD, Chang Y, Duseja A, et al. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement. Hepatol Commun. 2024;8(2):e0386.","journal-title":"Hepatol Commun"},{"key":"4787_CR29","doi-asserted-by":"crossref","unstructured":"Qayed E, Migdal AL, Jagannathan R, Miller LS, Pasquel FJ. Characteristics and outcomes of Black and White patients hospitalized with nonalcoholic steatohepatitis: a nationwide analysis. J Clin Gastroenterol. 2022.","DOI":"10.1097\/MCG.0000000000001698"},{"issue":"4","key":"4787_CR30","first-page":"362","volume":"10","author":"G Pemmasani","year":"2020","unstructured":"Pemmasani G, Yandrapalli S, Aronow W. Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. Am J Cardiovasc Dis. 2020;10(4):362\u20136.","journal-title":"Am J Cardiovasc Dis"},{"issue":"6","key":"4787_CR31","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966.","journal-title":"Hepatology"},{"issue":"6","key":"4787_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ijo.2008.11","volume":"32","author":"A Romero-Corral","year":"2008","unstructured":"Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes. 2008;32(6):959\u201366.","journal-title":"Int J Obes"},{"issue":"5","key":"4787_CR33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/hep.30049","volume":"68","author":"G Kim","year":"2018","unstructured":"Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology. 2018;68(5):1755\u201368.","journal-title":"Hepatology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04787-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:35:54Z","timestamp":1779060954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04787-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4787"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04787-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The linked dataset used in this analysis contains de-identified data as per the de-identification standard defined in Section \u00a7\u00a0164.514(a) of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7\u00a0164.514(b)(1) of the HIPAA Privacy Rule.U.S. law 45 Code of Federal Regulations Part 46, human participant protection regulations, and Protection of Human Subjects (45 CFR 46) requires institutional review board (IRB) approval for all research involving identifiable private information or identifiable biospecimens from human subjects as defined in 45 CFR 46.102(e)(5) and in 45 CFR 46.102(e)(6). However, protected health information that has been de-identified under the standard set for in 45 CFR 164.514(b)(1) is no longer considered to be identifiable health information and therefore is no longer subject to the IRB requirements set forth in 45 CFR 46. Because this study used only de-identified records, it is therefore no longer subject to the HIPAA Privacy Rule, the requirements for informed consent, or the IRB requirements set forth in 45 CFR 46. This study was conducted in compliance with the Declaration of Helsinki and used only de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.R., D.L., J.P.W., and M.B. are employees of Veradigm, which received fees from Madrigal Pharmaceuticals related to this work. Y.K. is an employee of Madrigal Pharmaceuticals. E.B.T. is an employee at the University of Michigan, which received unrestricted financial support to the institution related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}